Sampre Nutritions Limited reported a standalone net profit of ₹70.21 lakh for the first quarter ended June 30, 2026, compared to ₹70.94 lakh in Q1FY26. Revenue from operations rose 36.6% year-on-year to ₹1,484.80 lakh, up from ₹1,086.65 lakh in the corresponding period of the previous year. The company also posted consolidated net profit of ₹70.21 lakh, with consolidated revenue matching the standalone figure at ₹1,484.80 lakh. These results reflect improved top-line growth despite stable profit margins.

The Board of Directors approved the financial results on August 5, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited results were reviewed by the statutory auditors, N G Rao & Associates, under Standard on Review Engagements (SRE) 2410. The Board also approved the notice for the 35th Annual General Meeting (AGM) scheduled for September 4, 2026, to be held via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

Key Financial Metrics

Note: Consolidated figures for revenue and net profit are identical to standalone figures.

Remuneration Revision Proposal

The Board approved a proposal to increase the remuneration of Vishal Ratan Gurbani, Whole-Time Director, from ₹18,00,000 per annum to ₹60,00,000 per annum. This revision is effective from April 1, 2026, and requires approval from members at the ensuing AGM. The Nomination and Remuneration Committee recommended this change. The approval relates solely to the revision in remuneration and does not constitute a fresh appointment or re-appointment; all other terms of his existing appointment remain unchanged.

What the Numbers Show

Revenue growth outpaced expense growth slightly in absolute terms but expenses rose at a marginally higher percentage rate (38.6%) compared to revenue (36.6%). This dynamic compressed the profit before tax margin slightly, although the absolute profit before tax increased by 12.6% to ₹79.88 lakh. Employee benefits expense was a major cost driver, rising to ₹509.93 lakh from ₹316.87 lakh year-on-year, indicating potential headcount expansion or wage adjustments. Finance costs decreased significantly to ₹25.69 lakh from ₹30.81 lakh, suggesting reduced debt burden or lower interest rates.

Sampre Nutritions Limited has closed its trading window for dealing in its securities effective from July 1, 2026, to prevent insider trading ahead of its financial results. The window will remain shut until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the first quarter of the financial year 2026-27 ending on June 30, 2026. The restriction applies to all promoters, directors, designated persons, specific connected persons, and their immediate relatives, who are advised not to trade in the company's securities during this closure period.

The decision is in accordance with Regulation 9 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and a specific SEBI circular dated July 19, 2023. Additionally, the closure follows the company's internal Code of Conduct designed to regulate, monitor, and report trading by designated persons. The company stated that the specific date for the Board of Directors meeting to declare the results for the quarter ending June 30, 2026, will be communicated in due course.

Key Details of the Closure

The intimation was submitted to BSE Limited on June 20, 2026, by Brahma Gurbani, Managing Director of Sampre Nutritions Limited.